KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for Esperion Therapeutics (ESPR) over the last 6 years, with Q3 2025 value amounting to $41.3 million.

  • Esperion Therapeutics' Cost of Revenue rose 13885.8% to $41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.0 million, marking a year-over-year increase of 13336.33%. This contributed to the annual value of $68.6 million for FY2024, which is 5855.27% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Cost of Revenue is $41.3 million, which was up 13885.8% from $28.5 million recorded in Q2 2025.
  • Esperion Therapeutics' Cost of Revenue's 5-year high stood at $41.3 million during Q3 2025, with a 5-year trough of $1.8 million in Q1 2021.
  • For the 5-year period, Esperion Therapeutics' Cost of Revenue averaged around $13.4 million, with its median value being $10.1 million (2024).
  • In the last 5 years, Esperion Therapeutics' Cost of Revenue soared by 565483.87% in 2021 and then tumbled by 2604.62% in 2023.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Cost of Revenue stood at $5.1 million in 2021, then decreased by 18.03% to $4.2 million in 2022, then soared by 175.29% to $11.5 million in 2023, then skyrocketed by 123.81% to $25.6 million in 2024, then surged by 61.09% to $41.3 million in 2025.
  • Its last three reported values are $41.3 million in Q3 2025, $28.5 million for Q2 2025, and $31.5 million during Q1 2025.